InflaRx announces initiation of its commitment program for GOHIBIC

InflaRx Pharmaceuticals, a subsidiary of InflaRx N.V., announced that the Company has launched The InflaRx Commitment Program. Pursuant to the Commitment Program, the cost of GOHIBIC will be refunded for up to six administered inpatient doses to institutions that meet the eligibility requirements, for patients who were administered GOHIBIC in line with its EUA and who died due to COVID-19 in the intensive care unit. In April 2023, the U.S. Food and Drug Administration, FDA, issued an EUA for GOHIBIC for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of the patient receiving invasive mechanical ventilation, IMV, or extracorporeal membrane oxygenation, ECMO. While GOHIBIC has been FDA authorized, it is not FDA approved for this use. Prof. Niels Riedemann, Chief Executive Officer, and Founder of InflaRx, commented: “COVID-19 continues to take far too many lives. Despite this unacceptable situation, patients do not always have access to approved or authorized treatment options. With today’s announcement, we are demonstrating our strong commitment to help make GOHIBIC available for the most affected COVID-19 patients as a potential life-saving therapy. There are currently no approved or authorized alternatives to GOHIBIC, and we believe that all eligible patients and the physicians responsible for their care should have access to this treatment.”